Herpes simplex virus type 1 (HSV-1) is a highly prevalent human neurotropic pathogen. HSV-1 infection is associated with a variety of diseases ranging from benign orolabial lesions to more serious and even life-threatening conditions such as herpes simplex keratitis and herpes simplex encephalitis (HSE). HSE is a rare occurrence among healthy adult individuals, but newborns are a particularly susceptible population. Type I IFN signaling has been identified as a crucial component of the innate immune response to the control of HSV-1 infection. In this study, we review the contribution of the type I IFN response to controlling HSV-1 infection, and differences in the early host response between adults and newborns that may contribute to the increased susceptibility to infection and central nervous system disease in newborns.
Get full access to this article
View all access options for this article.
References
1.
AdkinsB., LeclercC., and Marshall-ClarkeS. (2004). Neonatal adaptive immunity comes of age. Nat Rev Immunol, 4, 553–564.
2.
AngeloneD.F., WesselsM.R., CoughlinM., SuterE.E., ValentiniP., KalishL.A., et al. (2006). Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-alpha production in vitro and in vivo. Pediatr Res, 60, 205–209.
3.
AravalliR.N., HuS., RowenT.N., PalmquistJ.M., and LokensgardJ.R. (2005). Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. J Immunol, 175, 4189–4193.
4.
AudryM., CiancanelliM., YangK., CobatA., ChangH-H., Sancho-ShimizuV., et al. (2011). NEMO is a key component of NF-κB- and IRF-3-dependent TLR3-mediated immunity to herpes simplex virus. J Allergy Clin Immunol, 128, 610.e1-4–617.e1-4.
5.
BagdadesE.K., PillayD., SquireS.B., O'NeilC., JohnsonM.A., and GriffithsP.D. (1992). Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS, 6, 1317–1320.
6.
BaringerJ.R., and SwovelandP. (1973). Recovery of herpes-simplex virus from human trigeminal ganglions. N Engl J Med, 288, 648–650.
7.
BradleyH., MarkowitzL.E., GibsonT., and McQuillanG.M. (2014). Seroprevalence of herpes simplex virus types 1 and 2—United States, 1999–2010. J Infect Dis, 209, 325–333.
8.
BrownZ.A., WaldA., MorrowR.A., SelkeS., ZehJ., and CoreyL. (2003). Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. J Am Med Assoc, 289, 203–209.
9.
CameronJ.S., AlexopoulouL., SloaneJ.A., DiBernardoA.B., MaY., KosarasB., et al. (2007). Toll-like receptor 3 is a potent negative regulator of axonal growth in mammals. J Neurosci, 27, 13033–13041.
10.
CasrougeA., ZhangS.-Y., EidenschenkC., JouanguyE., PuelA., YangK., et al. (2006). Herpes simplex virus encephalitis in human UNC-93B deficiency. Science, 314, 308–312.
11.
ChouJ., and RoizmanB. (1992). The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. PNAS, 89, 3266–3270.
12.
ChouJ., and RoizmanB. (1994). Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. PNAS, 91, 5247–5251.
13.
CliffeA.R., ArbuckleJ.H., VogelJ.L., GedenM.J., RothbartS.B., CusackC.L., et al. (2015). Neuronal stress pathway mediating a histone methyl/phospho switch is required for herpes simplex virus reactivation. Cell Host Microbe, 18, 649–658.
14.
CoreyL., and WaldA. (2009). Maternal and neonatal herpes simplex virus infections. N Engl J Med, 361, 1376–1385.
GarciaA.M., FadelS.A., CaoS., and SarzottiM. (2000). T cell immunity in neonates. Immunol Res, 22, 177–190.
17.
GillN., DeaconP.M., LichtyB., MossmanK.L., and AshkarA.A. (2006). Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of toll-like receptor ligands correlates with beta interferon production. J Virol, 80, 9943–9950.
18.
GobeilP.A.M., and LeibD.A. (2012). Herpes simplex virus γ34.5 interferes with autophagosome maturation and antigen presentation in dendritic cells. MBio, 3, e00267-12.
19.
GresserI., ToveyM.G., MauryC., and BanduM.T. (1976). Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses. J Exp Med, 144, 1316–1323.
20.
GuoY., AudryM., CiancanelliM., AlsinaL., AzevedoJ., HermanM., et al. (2011). Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J Exp Med, 208, 2083–2098.
21.
HayK.A., GaydosA., and TenserR.B. (1995). The role of herpes simplex thymidine kinase expression in neurovirulence and latency in newborn vs. adult mice. J Neuroimmunol, 61, 41–52.
22.
HeB., GrossM., and RoizmanB. (1997). The γ134.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1α to dephosphorylate the α subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci U S A, 94, 843–848.
23.
HergetG.W., RiedeU.N., Schmitt-GräffA., LübbertM., Neumann-HaefelinD., and KöhlerG. (2005). Generalized herpes simplex virus infection in an immunocompromised patient–report of a case and review of the literature. Pathol Res Pract, 201, 123–129.
24.
HermanM., CiancanelliM., OuY-H., LorenzoL., Klaudel-DreszlerM., PauwelsE., et al. (2012). Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J Exp Med, 209, 1567–1582.
25.
JacquemontB., and RoizmanB. (1975). RNA synthesis in cells infected with herpes simplex virus. X. Properties of viral symmetric transcripts and of double-stranded RNA prepared from them. J Virol, 15, 707–713.
26.
JamesS.H., and KimberlinD.W. (2015). Neonatal herpes simplex virus infection: epidemiology and treatment. Clin Perinatol, 42, 47–59.
27.
JohnsonK.E., BotteroV., FlahertyS., DuttaS., SinghV.V., and ChandranB. (2014). IFI16 restricts HSV-1 replication by accumulating on the HSV-1 genome, repressing HSV-1 gene expression, and directly or indirectly modulating histone modifications. PLOS Pathogens, 10, e1004503.
28.
KawaiT., and AkiraS. (2007). Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med, 13, 460–469.
29.
KimJ.C., LeeS.Y., KimS.Y., KimJ.K., KimH.J., LeeH.M., et al. (2008). HSV-1 ICP27 suppresses NF-kappaB activity by stabilizing IkappaBalpha. FEBS Lett, 582, 2371–2376.
KoppS.J., KarabaA.H., CohenL.K., BanisadrG., MillerR.J., and MullerW.J. (2013). Pathogenesis of neonatal herpes simplex 2 disease in a mouse model is dependent on entry receptor expression and route of inoculation. J Virol, 87, 474–481.
32.
KoppS.J., RanaivoH.R., WilcoxD.R., KarabaA.H., WainwrightM.S., and MullerW.J. (2014). Herpes simplex virus serotype and entry receptor availability alter CNS disease in a mouse model of neonatal HSV. Pediatr Res, 76, 528–534.
33.
KrugA., LukerG.D., BarchetW., LeibD.A., AkiraS., and ColonnaM. (2004). Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood, 103, 1433–1437.
34.
Kurt-JonesE.A., ChanM., ZhouS., WangJ., ReedG., BronsonR., et al. (2004). Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci U S A, 101, 1315–1320.
35.
LeibD.A., HarrisonT.E., LasloK.M., MachalekM.A., MoormanN.J., and VirginH.W. (1999). Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J Exp Med, 189, 663–672.
36.
LeibD.A., MachalekM.A., WilliamsB.R., SilvermanR.H., and VirginH.W. (2000). Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc Natl Acad Sci U S A, 97, 6097–6101.
37.
LeoniV., GianniT., SalvioliS., and Campadelli-FiumeG. (2012). Herpes simplex virus glycoproteins gH/gL and gB Bind Toll-like receptor 2, and soluble gH/gL is sufficient to activate NF-κB. J Virol, 86, 6555–6562.
38.
LiX.D., WuJ., GaoD., WangH., SunL., and ChenZ.J. (2013). Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science, 341, 1390–1394.
39.
LiuS., CaiX., WuJ., CongQ., ChenX., LiT., et al. (2015). Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science, 347, aaa2630.
40.
LopezC. (1975). Genetics of natural resistance to herpesvirus infections in mice. Nature, 258, 152–153.
41.
MaY., and HeB. (2014). Recognition of herpes simplex viruses: toll-like receptors and beyond. J Mol Biol, 426, 1133–1147.
42.
MalmgaardL., MelchjorsenJ., BowieA.G., MogensenS.C., and PaludanS.R. (2004). Viral activation of macrophages through TLR-dependent and -independent pathways. J Immunol, 173, 6890–6898.
MelroeG.T., SilvaL., SchafferP.A., and KnipeD.M. (2007). Recruitment of activated IRF-3 and CBP/p300 to herpes simplex virus ICP0 nuclear foci: potential role in blocking IFN-beta induction. Virology, 360, 305–321.
45.
MeyersJ.D., FlournoyN., and ThomasE.D. (1980). Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis, 142, 338–346.
46.
MilliganG.N., and BernsteinD.I. (1995). Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract. Virology, 206, 234–241.
47.
MilliganG.N., and BernsteinD.I. (1997). Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology, 229, 259–268.
48.
MurphyA.A., RosatoP.C., ParkerZ.M., KhalenkovA., and LeibD.A. (2013). Synergistic control of herpes simplex virus pathogenesis by IRF-3, and IRF-7 revealed through non-invasive bioluminescence imaging. Virology, 444, 71–79.
49.
NingS., PaganoJ.S., and BarberG.N. (2011). IRF7: activation, regulation, modification and function. Genes Immun, 12, 399–414.
50.
OrvedahlA., AlexanderD., TallóczyZ., SunQ., WeiY., ZhangW., et al. (2007). HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe, 1, 23–35.
51.
OrzalliM.H., BroekemaN.M., DinerB.A., HancksD.C., EldeN.C., CristeaI.M., et al. (2015). cGAS-mediated stabilization of IFI16 promotes innate signaling during herpes simplex virus infection. PNAS, 112, E1773–E1781.
52.
ParkerZ.M., MurphyA.A., and LeibD.A. (2015). Role of the DNA sensor STING in protection from lethal infection following corneal and intracerebral challenge with herpes simplex virus 1. J Virol, 89, 11080–11091.
53.
PebodyR.G., AndrewsN., BrownD., GopalR., De MelkerH., FrançoisG., et al. (2004). The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. Sex Transm Infect, 80, 185–191.
54.
PedersenE.B., HaahrS., and MogensenS.C. (1983). X-linked resistance of mice to high doses of herpes simplex virus type 2 correlates with early interferon production. Infect Immun, 42, 740–746.
55.
Pérez de DiegoR., Sancho-ShimizuV., LorenzoL., PuelA., PlancoulaineS., PicardC., et al. (2010). Human TRAF3 adaptor molecule deficiency leads to impaired toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity, 33, 400–411.
56.
RajeshK., KrishnamoorthyJ., KazimierczakU., TenkerianC., PapadakisA.I., WangS., et al. (2015). Phosphorylation of the translation initiation factor eIF2α at serine 51 determines the cell fate decisions of Akt in response to oxidative stress. Cell Death Dis, 6, e1591.
57.
Sancho-ShimizuV., Perez de DiegoR., JouanguyE., ZhangS.-Y., and CasanovaJ.-L. (2011a). Inborn errors of anti-viral interferon immunity in humans. Curr Opin Virol, 1, 487–496.
58.
Sancho-ShimizuV., Pérez de DiegoR., LorenzoL., HalwaniR., AlangariA., IsraelssonE., et al. (2011b). Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J Clin Invest, 121, 4889–4902.
59.
ShuaiK., HorvathC.M., HuangL.H., QureshiS.A., CowburnD., and DarnellJ.E. (1994). Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell, 76, 821–828.
van LintA.L., MurawskiM.R., GoodbodyR.E., SeveraM., FitzgeraldK.A., FinbergR.W., et al. (2010). Herpes simplex virus immediate-early ICP0 protein inhibits Toll-like receptor 2-dependent inflammatory responses and NF-κB signaling. J Virol, 84, 10802–10811.
62.
VerpootenD., MaY., HouS., YanZ., and HeB. (2009). Control of TANK-binding kinase 1-mediated signaling by the gamma(1)34.5 protein of herpes simplex virus 1. J Biol Chem, 284, 1097–1105.
63.
WaldA., and CoreyL. (2007). Persistence in the population: epidemiology, transmission. In Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. ArvinA., Campadelli-FiumeG., MocarskiE., MooreP.S., RoizmanB., WhitleyR., et al. eds. (Cambridge University Press, Cambridge), pp. 656–674.
64.
WilcoxD.R., FolmsbeeS.S., MullerW.J., and LongneckerR. (2016). The Type I Interferon response determines differences in choroid plexus susceptibility between newborns and adults in herpes simplex virus encephalitis. MBio, 7, e00437–16.
65.
WilcoxD.R., and LongneckerR. (2016). The herpes simplex virus neurovirulence factor γ34.5: revealing virus-host interactions. PLOS Pathogens, 12, e1005449.
66.
WilcoxD.R., MullerW.J., and LongneckerR. (2015a). HSV targeting of the host phosphatase PP1α is required for disseminated disease in the neonate and contributes to pathogenesis in the brain. Proc Natl Acad Sci U S A, 112, E6937–E6944.
67.
WilcoxD.R., WadhwaniN.R., LongneckerR., and MullerW.J. (2015b). Differential reliance on autophagy for protection from HSV encephalitis between newborns and adults. PLOS Pathogens, 11, e1004580.
68.
WuJ., and ChenZ.J. (2014). Innate immune sensing and signaling of cytosolic nucleic acids. Ann Rev Immunol, 32, 461–488.
69.
XuF., SternbergM.R., KottiriB.J., McQuillanG.M., LeeF.K., NahmiasA.J., et al. (2006). Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. J Am Med Assoc, 296, 964–973.
70.
ZawatzkyR., EnglerH., and KirchnerH. (1982a). Experimental infection of inbred mice with herpes simplex virus. III. Comparison between newborn and adult C57BL/6 mice. J Gen Virol, 60, 25–29.
71.
ZawatzkyR., GresserI., DeMaeyerE., and KirchnerH. (1982b). The role of interferon in the resistance of C57BL/6 mice to various doses of herpes simplex virus type 1. J Infect Dis, 146, 405–410.
72.
ZhangS.-Y., JouanguyE., UgoliniS., SmahiA., ElainG., RomeroP., et al. (2007). TLR3 deficiency in patients with herpes simplex encephalitis. Science (New York, NY), 317, 1522–1527.
